Kazia Therapeutics (KZIA) currently has a strong positive outlook from analysts, with a consensus rating of "Strong Buy" based on 3 recent analyst ratings. The average price target across these analysts is around $16 to $16.50, suggesting a significant upside potential from the current trading price near $5.76 to $9.78. Individual price targets range from a low of $13 (HC Wainwright & Co.) to a high of $20 (Maxim Group as of October 2025), indicating potential gains of approximately 63% to over 100% in the next 12 months. Key analysts maintaining or initiating "Strong Buy" ratings include Maxim Group and HC Wainwright & Co.?
Market Data 
Markets 
AI
